Feasibility and patient acceptability of a commercially available wearable and a smart phone application in identification of motor states in parkinson's disease.

Autor: Sammeli Liikkanen, Janne Sinkkonen, Joni Suorsa, Valtteri Kaasinen, Eero Pekkonen, Mikko Kärppä, Filip Scheperjans, Teppo Huttunen, Toni Sarapohja, Ullamari Pesonen, Mikko Kuoppamäki, Tapani Keränen

Publikováno v: PLOS Digital Health, Vol 2, Iss 4, p e0000225 (2023)

In the quantification of symptoms of Parkinson's disease (PD), healthcare professional assessments, patient reported outcomes (PRO), and medical device grade wearables are currently used. Recently, also commercially available smartphones and wearable

Externí odkaz: https://doaj.org/article/012d6c5856004986a94efd8d4883e5a0

Efficacy and safety of darolutamide in Black/African–American patients from the phase III ARAMIS study

Autor: Neal D Shore, Felipe Cruz, Luke Nordquist, Laurence Belkoff, William J Aronson, Bhupendra Tolia, Arnold Cinman, Roohollah Sharifi, Jorge Ortiz, Jacqueline Parkin, Shankar Srinivasan, Toni Sarapohja, Matthew R Smith

Publikováno v: Future Oncology. 18:4473-4482

Aim: Darolutamide significantly improved metastasis-free survival (MFS) and overall survival (OS) versus placebo in the phase III ARAMIS study. We evaluated outcomes in Black/African–American patients in ARAMIS. Materials & methods: Patients with n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fa2939ba367547b5e95eb45a9583e30c
https://doi.org/10.2217/fon-2022-0943

Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial

Autor: Michael Pulley, Mikko Kuoppamäki, Carolyn A Young, Jesus S. Mora Pardina, Kumaraswamy Sivakumar, Toni Sarapohja, Michael A. Elliott, Chafic Karam, Sandeep Rana, Orla Hardiman, Nathan P. Staff, Letizia Mazzini, Gabriele Mora, Thomas F. Meyer, Colleen O'Connell, Stéphanie Delstanche, Elham Bayat, Michael D. Weiss, Waqar Waheed, Nenad Mitrovic, Philippe Corcia, Marie-Hélène Soriani, Edward J. Kasarskis, Claudia Caponnetto, Dale J. Lange, Tuan Vu, Leo McCluskey, Berthold Schrank, Angela Genge, Matthew C. Kiernan, Valtteri V Aho, Manu Jokela, Philip Van Damme, Juan F. Vázquez Costa, Maurizio Inghilleri, Wolfgang Löscher, David Schultz, Tero Tapiola, Susanne Petri, Adriano Chiò, Gary L. Pattee, Julian Großkreutz, Ammar Al-Chalabi, Aziz Shaibani, Susan Mathers, Kevin J. Felice, Kimberly Goslin, James Caress, Matthias Boentert, Albert C. Ludolph, Aleksandar Radunovic, Robert D. Henderson, James Wymer, Todd Levine, Jakob Rath, Merrilee Needham, William Camu, Gaurav Guliani, Rune Johansson, Leonard H. van den Berg, Namita Goyal, Mark B. Bromberg, Bjorn Oskarsson, Annie Dionne, Eduardo Locatelli, Brent T. Harris, Suma Babu, Richard Bedlack, John Ravits, Jinsy A. Andrews, Philippe Couratier, Gabriele Siciliano, Hannu Laaksovirta, Kourosh Rezania, Lawrence Korngut, Eduardo Aguera Morales, Peter M Andersen, Eva Farrero Munoz, David Lacomis, Stephen N. Scelsa, Chris Garratt, Matthew Burford, Merit Cudkowicz, Nicholas J. Maragakis, Wendy Johnston, Martin M. Brown, Johannes Prudlo, Justin Y. Kwan, Dominic B. Fee, Senda Ajroud-Driss, Stephen A. Goutman, John Turnbull, Michael H. Rivner, Timothy M. Miller, Jan De Bleecker, Caroline Ingre, Luis Varona, Genevieve Matte, Daragh Heitzman, Robert Untucht, Lorne Zinman, Adam Quick, Jonathan S. Katz

Publikováno v: The Lancet Neurology. 20:821-831

Summary Background There is an urgent unmet need for new therapies in amyotrophic lateral sclerosis. In a clinical study with healthy volunteers, levosimendan, a calcium sensitiser, was shown to improve neuromechanical efficiency and contractile func

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47e159b8bed1a737713c1c2f5bf0a571
https://doi.org/10.1016/s1474-4422(21)00242-8

Efficacy and safety of darolutamide in patients with nonmetastatic castration-resistant prostate cancer stratified by prostate-specific antigen doubling time: planned subgroup analysis of the phase 3 ARAMIS trial

Autor: Martin Bögemann, Neal D. Shore, Matthew R. Smith, Teuvo L.J. Tammela, Albertas Ulys, Egils Vjaters, Sergey Polyakov, Mindaugas Jievaltas, Murilo Luz, Boris Alekseev, Thierry Lebret, Martin Schostak, Frank Verholen, Marie-Aude Le Berre, Shankar Srinivasan, Jorge Ortiz, Ateesha F. Mohamed, Toni Sarapohja, Karim Fizazi

Publikováno v: European urology, Amsterdam : Elsevier B.V., 2023, vol. 83, iss. 3, p. 212-221

Background: Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have a high risk of progression to metastatic disease, particularly if their prostate-specific antigen doubling time (PSADT) is ≤6 mo. However, patients remain at

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32b5b416d27420ef8e9925225f89d480
https://repository.vu.lt/VU:ELABAPDB153215389&prefLang=en_US

A prospective, double-blind, pilot, randomized, controlled trial of an 'embodied' virtual reality intervention for adults with low back pain

Autor: Christopher Eccleston, Emma Fisher, Sammeli Liikkanen, Toni Sarapohja, Carina Stenfors, Satu K. Jääskeläinen, Andrew S.C. Rice, Leena Mattila, Taru Blom, J. Raymond Bratty

Publikováno v: Eccleston, C, Fisher, E, Liikkanen, S, Sarapohja, T, Stenfors, C, Jääskeläinen, S K, Rice, A S C, Mattila, L, Blom, T & Bratty, J R 2022, ' A prospective, double-blind, pilot, randomized, controlled trial of an "embodied" virtual reality intervention for adults with low back pain ', Pain, vol. 163, no. 9, pp. 1700-1715 . https://doi.org/10.1097/j.pain.0000000000002617

Adults with chronic low back pain, disability, moderate-to-severe pain, and high fear of movement and reinjury were recruited into a trial of a novel, automated, digital therapeutics, virtual reality, psychological intervention for pain (DTxP). We co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44cd7c6c22b974f42137b5e8e0901c2b
https://pubmed.ncbi.nlm.nih.gov/35324507